results of a phase ii trial of vidutolimod and nivolumab in melanoma
Published 1 year ago • 210 plays • Length 2:58Download video MP4
Download video MP3
Similar videos
-
1:09
vidutolimod, a novel tlr9 agonist, in high-risk resectable melanoma
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
2:34
dr. pavlick on a phase ii trial of cyclophosphamide and ipilimumab in melanoma
-
0:49
scandium 2: ihp with ipilimumab and nivolumab in uveal melanoma metastases
-
1:20
pixatimod and nivolumab in metastatic melanoma, nsclc and mss crc
-
1:26
metastatic melanoma: the checkmate 067 and 069 trials
-
2:14
immuned: adjuvant nivolumab and ipilimumab increases os in stage iv melanoma
-
2:00
clinical trial tests nivolumab for patients with rare brain and spine cancers
-
1:12
current trials in the treatment of melanoma
-
0:46
the benefits of nivolumab and relatlimab in melanoma
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
10:42
what is new in melanoma?
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
2:05
dr. jeffrey weber explores nivolumab in advanced melanoma
-
6:21
new long-term data 'clearly favor' combination ipilimumab/nivolumab in melanoma
-
4:27
key updates in immunotherapies for melanoma
-
1:02
dr. hodi on nivolumab in combination with ipilimumab for advanced melanoma
-
1:17
treatment selection for stage iii braf-mutant melanoma
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma